217 related articles for article (PubMed ID: 30219698)
41. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
42. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P
Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
[TBL] [Abstract][Full Text] [Related]
43. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
44. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.
van Besien K; Carreras J; Bierman PJ; Logan BR; Molina A; King R; Nelson G; Fay JW; Champlin RE; Lazarus HM; Vose JM; Hari PN
Biol Blood Marrow Transplant; 2009 May; 15(5):554-63. PubMed ID: 19361747
[TBL] [Abstract][Full Text] [Related]
45. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
46. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.
Smith SM; Burns LJ; van Besien K; Lerademacher J; He W; Fenske TS; Suzuki R; Hsu JW; Schouten HC; Hale GA; Holmberg LA; Sureda A; Freytes CO; Maziarz RT; Inwards DJ; Gale RP; Gross TG; Cairo MS; Costa LJ; Lazarus HM; Wiernik PH; Maharaj D; Laport GG; Montoto S; Hari PN
J Clin Oncol; 2013 Sep; 31(25):3100-9. PubMed ID: 23897963
[TBL] [Abstract][Full Text] [Related]
47. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
[TBL] [Abstract][Full Text] [Related]
48. Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis.
Shah NN; Ahn KW; Litovich C; Sureda A; Kharfan-Dabaja MA; Awan FT; Ganguly S; Gergis U; Inwards D; Karmali R; Lazaryan A; Lekakis L; Munshi P; Nathan S; Saad AA; Solh M; Steinberg A; Vij R; Wood WA; Fenske TS; Smith S; Hamadani M
Blood Cancer J; 2019 Dec; 9(12):97. PubMed ID: 31796726
[TBL] [Abstract][Full Text] [Related]
49. Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis.
William BM; Wang T; Haagenson MD; Fleischhauer K; Verneris M; Hsu KC; de Lima MJ; Fernandez-Viña M; Spellman SR; Lee SJ; Hill BT
Biol Blood Marrow Transplant; 2018 Apr; 24(4):827-831. PubMed ID: 29155319
[TBL] [Abstract][Full Text] [Related]
50. Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Aldoss I; Tsai NC; Slovak ML; Palmer J; Alvarnas J; Marcucci G; Forman SJ; Pullarkat V
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1212-1217. PubMed ID: 27044907
[TBL] [Abstract][Full Text] [Related]
51. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel S; Labopin M; Socié G; Beelen D; Browne P; Volin L; Kyrcz-Krzemien S; Yakoub-Agha I; Aljurf M; Wu D; Michallet M; Arnold R; Mohty M; Nagler A
Haematologica; 2017 Jan; 102(1):139-149. PubMed ID: 27686376
[TBL] [Abstract][Full Text] [Related]
52. Unrelated donor allogeneic hematopoietic cell transplantation is underused as a curative therapy in eligible patients from the United States.
Yao S; Hahn T; Zhang Y; Haven D; Senneka M; Dunford L; Parsons S; Confer D; McCarthy PL
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1459-64. PubMed ID: 23811537
[TBL] [Abstract][Full Text] [Related]
53. Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort Analysis.
Wudhikarn K; Johnson BM; Inwards DJ; Porrata LF; Micallef IN; Ansell SM; Hogan WJ; Paludo J; Villasboas JC; Johnston PB
Transplant Cell Ther; 2023 Mar; 29(3):176.e1-176.e8. PubMed ID: 36563788
[TBL] [Abstract][Full Text] [Related]
54. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
[TBL] [Abstract][Full Text] [Related]
55. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
[TBL] [Abstract][Full Text] [Related]
56. Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis.
Derigs P; Bethge WA; Krämer I; Holtick U; von Tresckow B; Ayuk F; Penack O; Vucinic V; von Bonin M; Baldus C; Mougiakakos D; Wulf G; Schnetzke U; Stelljes M; Fante M; Schroers R; Kroeger N; Dreger P;
Transplant Cell Ther; 2023 Dec; 29(12):750-756. PubMed ID: 37709204
[TBL] [Abstract][Full Text] [Related]
57. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.
Dodero A; Spina F; Narni F; Patriarca F; Cavattoni I; Benedetti F; Ciceri F; Baronciani D; Scimè R; Pogliani E; Rambaldi A; Bonifazi F; Dalto S; Bruno B; Corradini P
Leukemia; 2012 Mar; 26(3):520-6. PubMed ID: 21904377
[TBL] [Abstract][Full Text] [Related]
58. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
[TBL] [Abstract][Full Text] [Related]
59. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
60. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study.
Ruggeri A; Battipaglia G; Labopin M; Ehninger G; Beelen D; Tischer J; Ganser A; Schwerdtfeger R; Glass B; Finke J; Michallet M; Stelljes M; Jindra P; Arnold R; Kröger N; Mohty M; Nagler A
J Hematol Oncol; 2016 Sep; 9(1):89. PubMed ID: 27639553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
